Nr Chandrasekar, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 25 Colts Xing, Canton, MA 02021 Phone: 617-285-9780 |
News Archive
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
By many estimates, an Ebola vaccine could be available in humans as early as next year. But will it be the right one? There are a number of vaccines in development and each is in a race to prove that it is most effective, safe and that it will protect the largest number of people.
The tar delivery of cigarettes is routinely measured with a machine and, with the exception of the United States, stated on every packet as a legal requirement in almost every country in the world. It is accompanied by measurement of nicotine and often carbon monoxide.
Today, public health and medical experts from the U.S. Department of Health and Human Services released the following statement on the Administration's plan for COVID-19 booster shots for the American people.
NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.
› Verified 1 days ago